PDK1 and colorectal carcinoma: Thus, in colorectal carcinoma (CRC) cells harboring the BRAFV600E mutation, phosphorylated PDK1 was found to inhibit the pyruvate dehydrogenase (PDH) complex or to induce mitochondrial fragmentation and, by so doing, to promote a glycolytic phenotype, clonogenic potential and metastatic advantage to tumor cells [70].